Intellia Therapeutics paused enrollment and dosing in two late‑stage trials after a volunteer receiving its CRISPR candidate for transthyretin amyloidosis was hospitalized with severe liver injury. The company disclosed the safety event in an investor call and said it is evaluating new safety measures while investigators review the case. The interruption affects Intellia’s nex‑z program (nexiguran ziclumeran) in ATTR cardiomyopathy and polyneuropathy and has prompted market and regulatory scrutiny of in vivo gene‑editing safety. The pause follows other recent liver concerns in the gene‑editing field and will delay near‑term development timelines as Intellia and regulators assess causality and mitigation steps. Clinical teams will monitor biomarkers of hepatic stress and refine protocols before resuming dosing; Intellia signaled the pause is temporary but material to trial timelines. For readers: in vivo CRISPR therapies introduce edits directly in patients’ tissues and therefore carry organ‑specific safety considerations tied to delivery and on‑target activity.